Reviva to Participate in the 2025 BIO CEO & Investor Conference

Rhea-AI Summary

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the 2025 BIO CEO & Investor Conference.

The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will be part of a panel discussion titled 'Tackling Mental Health through New Targets and Endpoints Progress'. The panel is scheduled for Tuesday, February 11, 2025, at 1:00 p.m. ET in New York, NY.

The conference will take place from February 10-11, 2025, and interested parties can register for the event and schedule one-on-one meetings with Reviva's management team.

News Market Reaction – RVPH

+2.79%

1 alert

+2.79% News Effect

On the day this news was published, RVPH gained 2.79%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY.

2025 BIO CEO & Investor Conference
Panel Title: Tackling Mental Health through New Targets and Endpoints Progress
Date: Tuesday, February 11, 2025
Time: 1:00 p.m. ET
Location: New York, NY

To register for the conference and schedule a one-on-one meeting with Reviva management, please use the link HERE.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. 

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When is Reviva Pharmaceuticals (RVPH) presenting at the 2025 BIO CEO Conference?

Reviva Pharmaceuticals will participate in a panel discussion on Tuesday, February 11, 2025, at 1:00 p.m. ET in New York.

What is the topic of RVPH's panel discussion at the 2025 BIO CEO Conference?

The panel discussion is titled 'Tackling Mental Health through New Targets and Endpoints Progress.'

What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?

Reviva focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.

Can investors meet with RVPH management at the 2025 BIO CEO Conference?

Yes, investors can register for the conference and schedule one-on-one meetings with Reviva's management team.

What are the dates for the 2025 BIO CEO & Investor Conference where RVPH is presenting?

The 2025 BIO CEO & Investor Conference is taking place on February 10-11, 2025.